Main Session
Sep
30
QP 38 - Lung Quick Pitch: Oligometastatic and Oligoprogressive NSCLC
1226 - Feasibility of Aumolertinib followed by SRT in EGFR+ NSCLC Patients with Intracranial Oligo-Progression: A Phase II, Prospective Study
Presenter(s)
Huiting Li, MD - Fudan University Shanghai Cancer Center, Shanghai, Shanghai